USA-based biotech firm bluebird bio (Nasdaq: BLUE) has announced a plan to split into two separate companies, with one focusing on severe genetic disease and another on oncology.
The strategy, which has been approved by the board, will result in the spinout of its oncology business, with current ‘chief bluebird’, Nick Leschly, becoming chief executive.
The current president of the severe genetic diseases business, Andrew Obenshain, will continue his leadership as chief executive of bluebird bio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze